{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:57:26Z","timestamp":1789567046339,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bone.2022.116480","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T03:55:25Z","timestamp":1656647725000},"page":"116480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study"],"prefix":"10.1016","volume":"162","author":[{"given":"Tomonori","family":"Kobayakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int."},{"issue":"9999","key":"10.1016\/j.bone.2022.116480_bb0010","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2022.116480_bb0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bone.2015.08.007","article-title":"Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats","volume":"81","author":"Ominsky","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116480_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"issue":"16","key":"10.1016\/j.bone.2022.116480_bb0025","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"15","key":"10.1016\/j.bone.2022.116480_bb0030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.bone.2022.116480_bb0035","article-title":"Real-world effects and adverse events of romosozumab in japanese osteoporotic patients: a prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone Rep."},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Scientific reports"},{"issue":"5","key":"10.1016\/j.bone.2022.116480_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"issue":"8","key":"10.1016\/j.bone.2022.116480_bb0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"MR","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2022.116480_bb0055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/jbmr.1472","article-title":"Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures","volume":"27","author":"Austin","year":"2012","journal-title":"J Bone Miner Res."},{"issue":"7041","key":"10.1016\/j.bone.2022.116480_bb0060","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.bone.2022.116480_bb0065","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"MR","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2022.116480_bb0070","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2022.116480_bb0075","series-title":"Report of a WHO Study Group","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis","volume":"843","year":"1994"},{"issue":"3","key":"10.1016\/j.bone.2022.116480_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","article-title":"Diagnostic criteria for primary osteoporosis: year 2012 revision","volume":"31","author":"Soen","year":"2013","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2022.116480_bb0090","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s00198-017-3967-6","article-title":"Total 25-hydroxyvitamin D levels predict fracture risk: results from the 15-year follow-up of the japanese population-based osteoporosis (JPOS) cohort study","volume":"28","author":"Tamaki","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2022.116480_bb0095","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00198-006-0127-9","article-title":"Comparison of BMD precision for Prodigy and Delphi spine and femur scans","volume":"17","author":"Shepherd","year":"2006","journal-title":"Osteoporos Int."},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2022.116480_bb0105","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstetrics and gynecology"},{"issue":"8","key":"10.1016\/j.bone.2022.116480_bb0110","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"6","key":"10.1016\/j.bone.2022.116480_bb0115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","article-title":"Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review","volume":"87","author":"Gallacher","year":"2010","journal-title":"Calcified tissue international"},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0120","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res."},{"key":"10.1016\/j.bone.2022.116480_bb0125","article-title":"Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis","author":"Ebina","year":"2022","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2022.116480_bb0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clnesp.2022.02.002","article-title":"Effects of romosozumab with and without active vitamin D analog supplementation for postmenopausal osteoporosis","volume":"48","author":"Kobayakawa","year":"2022","journal-title":"Clin Nutr ESPEN."},{"issue":"2","key":"10.1016\/j.bone.2022.116480_bb0135","first-page":"174","article-title":"Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs","volume":"7","author":"Schacht","year":"2007","journal-title":"Journal of musculoskeletal & neuronal interactions"},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0140","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13018-020-01896-z","article-title":"The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis","volume":"15","author":"Zheng","year":"2020","journal-title":"Journal of orthopaedic surgery and research"},{"issue":"5","key":"10.1016\/j.bone.2022.116480_bb0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00774-016-0792-5","article-title":"Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis","volume":"35","author":"Ebina","year":"2017","journal-title":"J. Bone Miner. Metab."},{"issue":"1","key":"10.1016\/j.bone.2022.116480_bb0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jos.2020.11.009","article-title":"Effects of eldecalcitol alone or a bone resorption inhibitor with eldecalcitol on bone mineral density, muscle mass, and exercise capacity for postmenopausal women with distal radius fractures","volume":"27","author":"Maeda","year":"2020","journal-title":"Journal of orthopaedic science\u202f: official journal of the Japanese Orthopaedic Association."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222001570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222001570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:03:24Z","timestamp":1757613804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222001570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":30,"alternative-id":["S8756328222001570"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116480","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116480"}}